Topical Drug Delivery Market Companies and Market Growth
- Galderma
- LEO Pharma
- Almirall
- AbbVie
- Sun Pharma
- Bausch Health
- Bausch + Lomb
- Santen Pharmaceutical
- Alcon
- Viatris
- Teva Pharmaceutical Industries
- Perrigo Company
- GSK
- Bayer Consumer Health
- Johnson & Johnson
- Hisamitsu Pharmaceutical
- Teikoku Pharma USA
- Kindeva Drug Delivery
- Corium, Inc.
- LTS Lohmann Therapie-Systeme
Market Growth
The global topical drug delivery market size is calculated at US$ 247.3 billion in 2024, grew to US$ 268.99 billion in 2025, and is projected to reach around US$ 568.65 billion by 2034. The market is expanding at a CAGR of 8.76% between 2025 and 2034.
What are the Key Trends in the Topical Drug Delivery Market?
- The respective market is driven by the growing aging population associated with a rise in skin concerns and breakthroughs in drug delivery technologies.
- In June 2025, DEBRA Research GmbH and Dermaliq Therapeutics, Inc., entered into a strategic, non-exclusive partnership to advance cutaneous drug delivery into the skin for EB.
- In January 2025, Gilead and LEO Pharma partnered to expand the development of the oral STAT6 program with potential in multiple inflammatory diseases, including atopic dermatitis.
The Market Value Chain Analysis
R&D
The global topical drug delivery market has specific steps in its R&D approaches, such as the discovery of novel molecules, formulating them into desired topical products, and testing their efficacy and safety through drug penetration.
Key Players: Bayer AG, 3M, Bausch Health Companies Inc., and Glenmark Pharmaceuticals, etc.
Formulation and Final Dosage Preparation
Inclusion of pre-formulation studies, like droplet size determination, zeta potential, size distribution, viscosity, pH, self-emulsification, cloud point, etc., further assists the assessment of formulation through membrane release and incorporation of additives in the final dosage.
Key Players: Johnson & Johnson, Novartis, Pfizer, and Kindeva Drug Delivery, etc.
Clinical Trials and Regulatory Approvals
In different phases of clinical trials, detection of the required dose, the drug’s safety, efficacy, and ultimately identifying possible adverse reactions or allergies occurring among patients are carried out. Also, this further supports the regulatory approval procedure of the topical drug delivery market.
Key Players: Cliantha Research, Dow Development Labs, Synapse Labs, US FDA, EMA, and other regulatory bodies etc.
Latest Announcements by Industry Leaders
- In February 2025, Sibel Health announced a collaboration with Maruho to co-develop and commercialize the ADAM AI wearable designed to reduce scratching among eczema sufferers. Evan Lund, Sibel's Head of Business Development for clinical trials, replied that the ADAM sensor is a robustly validated digital endpoint for scratch monitoring in clinical trials and expands digital health technologies.
- In November 2024, Akums Drugs & Pharmaceuticals Ltd. announced that it had entered into an in-licensing agreement with Caregen Co., Ltd., a biotechnology player based in South Korea, to expand topical and injectable cosmeceuticals, including advanced Skinceuticals and Hairceuticals. Sanjeev Jain, Managing Director of Akums, stated that this will help launch novel and impactful products to help individuals look and feel their best.
What are Recent Developments in the Developing Market?
- In July 2025, Pelthos Therapeutics Inc., a biopharmaceutical company, launched ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older.
- In March 2025, L’Oréal Groupe unveiled L’Oréal Act for Dermatology, a €20 million, five-year programme led by its Dermatological Beauty Division that focused on democratizing access to skin health in support of the 2.1 billion people in the world living with skin disease.
- In February 2025, Aveva Drug Delivery Systems, a leader in transdermal drug delivery systems, introduced all strengths of its generic Fentanyl Transdermal Patch in the US market.
Become a valued research partner with us, please feel free to contact us at sales@towardshealthcare.com
